Table 1.
Characteristics of the 168 patients who received proton beam therapy for localized prostate cancer.
| Time of Day for Proton Beam Therapy | |||||
|---|---|---|---|---|---|
| Morning | Around Noon | Late Afternoon | |||
| (08:30–10:30) | (10:31–14:30) | (14:31–16:30) | Total | p Value | |
| No. patients (%) | 52 (31.0) | 64 (38.1) | 52 (31.0) | 168 | |
| Age at proton therapy (median [range], years) | 68 (57–80) | 67 (56–86) | 68.5 (53–86) | 68 (53–86) | 0.8 |
| Initial PSA (median [range], ng/mL) | 10.3 (3.5–220) | 7.66 (3.5–143) | 8.3 (1.6–150) | 8.6 (1.6–220) | 0.39 |
| Gleason score at prostate biopsy (n, %) | 0.37 | ||||
| 6 | 10 (19.2) | 13 (20.3) | 6 (11.5) | 29 (17.3) | |
| 7 | 20 (38.5) | 30 (46.9) | 21 (40.4) | 71 (42.3) | |
| 8 | 15 (28.9) | 15 (23.4) | 13 (25) | 43 (25.6) | |
| 9 | 6 (11.5) | 5 (7.8) | 12 (23.1) | 23 (13.7) | |
| 10 | 1 (1.9) | 1 (1.6) | 0 | 2 (1.2) | |
| Clinical T stage (n, %) | 0.77 | ||||
| T1 | 12 (23.1) | 16 (25) | 10 (19.2) | 33 (22.6) | |
| T2 | 27 (51.9) | 35 (54.7) | 26 (50) | 88 (52.4) | |
| T3 | 13 (25) | 13 (20.3) | 16 (30.8) | 42 (25.0) | |
| NCCN risk classification (n, %) | 0.67 | ||||
| Low | 7 (13.5) | 9 (14.1) | 4 (7.7) | 20 (11.9) | |
| Intermediate | 20 (38.5) | 26 (40.6) | 18 (34.6) | 64 (38.1) | |
| High | 25 (48.1) | 29 (45.3) | 30 (57.7) | 84 (50.0) | |
| ADT (n, %) | 46 (88.5) | 52 (81.3) | 48 (92.3) | 146 (86.9) | 0.21 |
| Fractional PBT dose (n, %) | 0.47 | ||||
| 2.0 Gy | 25 (48.1) | 24 (37.5) | 24 (46.2) | 73 (43.5) | |
| 2.5 Gy | 27 (51.9) | 40 (62.5) | 28 (53.9) | 95 (56.5) | |
| CTV (median [range], mL) | 29.8 (15.1–61.9) | 29.5 (16.9–98.6) | 28 (16.4–87.1) | 29 (15–84) | 0.7 |
| IPSS total score (median [range]) | 8 (0–18) | 8.5 (0–24) | 8 (0–20) | 8 (0–24) | 0.84 |
| Severity of IPSS (n, %) | 0.44 | ||||
| Mild | 24 (46.2) | 26 (40.6) | 25 (48.1) | 75 (44.6) | |
| Moderate | 28 (53.9) | 34 (53.1) | 26 (50) | 88 (52.4) | |
| Severe | 0 (0) | 4 (6.3) | 1 (1.9) | 5 (3.0) | |
| IPSS-QoL score (median [range]) | 2 (0–5) | 2 (0–6) | 2 (0–6) | 2 (0–6) | 0.79 |
| LUTS medication use before PBT (n, %) | 3 (5.8) | 8 (12.5) | 3 (5.8) | 14 (8.3) | 0.31 |
| Diabetes (n, %) | 14 (26.9) | 11 (17.2) | 8 (15.4) | 33 (19.6) | 0.29 |
| Anti-coagulant therapy (n, %) | 9 (17.3) | 8 (12.5) | 8 (13.4) | 25 (14.9) | 0.8 |
Prostate-specific antigen (PSA); National Comprehensive Cancer Network (NCCN); androgen deprivation therapy (ADT); proton beam therapy (PBT); clinical target volume (CTV); international prostate symptom score (IPSS); lower urinary tract symptoms (LUTS).